Oppenheimer resumed coverage on Cyclacel Pharma with a new price target
$CYCC
Biotechnology: Pharmaceutical Preparations
Health Care
Oppenheimer resumed coverage of Cyclacel Pharma with a rating of Outperform and set a new price target of $17.00
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 7/18/2022 | $17.00 | Outperform | Oppenheimer |
8-K - Bio Green Med Solution, Inc. (0001130166) (Filer)
425 - Cyclacel Pharmaceuticals, Inc. (0001130166) (Subject)
8-K - Cyclacel Pharmaceuticals, Inc. (0001130166) (Filer)
3 - Bio Green Med Solution, Inc. (0001130166) (Issuer)
4 - Cyclacel Pharmaceuticals, Inc. (0001130166) (Issuer)
4 - Cyclacel Pharmaceuticals, Inc. (0001130166) (Issuer)
Oppenheimer resumed coverage of Cyclacel Pharma with a rating of Outperform and set a new price target of $17.00
Oppenheimer initiated coverage of Cyclacel Pharmaceuticals with a rating of Outperform and set a new price target of $17.00
4 - Cyclacel Pharmaceuticals, Inc. (0001130166) (Issuer)
4 - Cyclacel Pharmaceuticals, Inc. (0001130166) (Issuer)
KUALA LUMPUR, Malaysia, Sept. 12, 2025 (GLOBE NEWSWIRE) -- Bio Green Med Solution, Inc. (NASDAQ:BGMS, NASDAQ:BGMSP) ("Bio Green Med" or the "Company"), a company engaged in diversified industries, today announced that it has closed the previously announced transaction (the "Exchange Transaction") to acquire Fitters Sdn. Bhd. ("Fitters"), a Malaysia private limited company and wholly-owned subsidiary of FITTERS Diversified Berhad, a Malaysian publicly listed company ("Fitters Parent"). Following the closing of the Exchange Transaction, which was approved by the Company's stockholders during a Special Meeting that took place on September 4, 2025, Fitters became a wholly-owned subsidiary of t
KUALA LUMPUR, Malaysia, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC, NASDAQ:CYCCP, ", Cyclacel", or the ", Company", )), a biopharmaceutical company developing innovative medicines, today announced its second quarter financial results and provided a business update. Highlights of the second quarter ended June 30, 2025, or in some cases shortly thereafter, include: In April, the Company announced that the Board of Directors of the Company declared a quarterly cash dividend of $0.15 per share on the Company's 6% Convertible Exchangeable Preferred Stock, which cash dividend was paid on May 1, 2025, to holders of 6% Convertible Exchangeable P
- Biliary tract cancer (BTC) or cholangiocarcinoma is an aggressive tumor with poor prognosis - KUALA LUMPUR, Malaysia, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC, NASDAQ:CYCCP, ", Cyclacel", or the ", Company", )), a biopharmaceutical company developing innovative cancer medicines, highlighted a preclinical study from independent investigators titled, "Evaluation of antitumor effects of plogosertib, PLK1 inhibitor in biliary tract cancer with BUBR1 as a potential biomarker" in the journal, Cancer Research, previously reported in a poster at the American Association of Cancer Research 2025 annual meeting.1 The investigators found that several BT
KUALA LUMPUR, Malaysia, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC, NASDAQ:CYCCP, ", Cyclacel", or the ", Company", )), a biopharmaceutical company developing innovative medicines, today announced its second quarter financial results and provided a business update. Highlights of the second quarter ended June 30, 2025, or in some cases shortly thereafter, include: In April, the Company announced that the Board of Directors of the Company declared a quarterly cash dividend of $0.15 per share on the Company's 6% Convertible Exchangeable Preferred Stock, which cash dividend was paid on May 1, 2025, to holders of 6% Convertible Exchangeable P
KUALA LUMPUR, MALAYSIA, May 15, 2025 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC, NASDAQ:CYCCP, ", Cyclacel", or the ", Company", )), a biopharmaceutical company developing innovative medicines, today announced its first quarter financial results and provided a business update. "As part of the Company's efforts to reduce operating costs it has determined to focus on the development of the plogosertib ("plogo") clinical program only. Accordingly, on March 10, 2025, the Company repurchased certain assets related to plogo from Cyclacel Limited for approximately $0.3 million in cash, to allow us to continue our efforts on developing an alternative salt, oral formulation of
BERKELEY HEIGHTS, N.J., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC, NASDAQ:CYCCP, ", Cyclacel", or the ", Company", )), a biopharmaceutical company developing innovative medicines, today announced third quarter financial results and provided a business update. "We were pleased to report initial safety and efficacy data from twelve patients with advanced solid tumors enrolled in the Phase 2 part of the 065-101, proof of concept, clinical study of fadraciclib as a single agent as a poster presentation at the 2024 EORTC-NCI-AACR 36th Symposium on Molecular Targets and Cancer Therapeutics ("Triple Meeting"), in Barcelona, Spain. The patients were enrolled in
BERKELEY HEIGHTS, N.J., April 02, 2025 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC, NASDAQ:CYCCP, "Cyclacel" or the "Company")), a biopharmaceutical company developing innovative medicines, today announced fourth quarter financial results and provided a business update. "As part of Cyclacel's efforts to reduce operating costs, it has determined to focus on the development of plogosertib, a polo-like kinase 1 (PLK 1) inhibitor for treatment of advanced cancers and hematological malignancies, which we acquired on March 10, 2025, from Cyclacel Limited, our wholly-owned subsidiary that is currently in liquidation," said Datuk Dr. Doris Wong Sing Ee, Chief Executive Officer
BERKELEY HEIGHTS, N.J., Jan. 30, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC, NASDAQ:CYCCP, ", Cyclacel", or the ", Company", ))), a biopharmaceutical company developing innovative medicines based on cancer cell biology, announced today that Brian Schwartz, M.D. will assume the role of interim Chief Medical Officer ("CMO") of the Company effective immediately. Dr. Schwartz will succeed Mark Kirschbaum, M.D., whose employment was terminated by the Company. "We are delighted to have Brian join Cyclacel as CMO. His extensive clinical and product development experience in oncology and hematology further adds to the strengths of our team and will support our efforts
– Anticancer Activity of Fadraciclib Monotherapy in Patients with MCL1 Amplified Solid Tumors–– Appointment of Mark Kirschbaum, M.D. as Chief Medical Officer –– $7 Million Strategic Investment by Fundamental Investor Acorn Bioventures– BERKELEY HEIGHTS, N.J., Jan. 11, 2021 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today provided a business update reviewing 2020 achievements and outlining the Company’s key business objectives for 2021. The Company will present at Biotech Showcase™ Digital 2021 taking place virtually from Januar
SC 13G/A - Cyclacel Pharmaceuticals, Inc. (0001130166) (Subject)
SC 13G - Cyclacel Pharmaceuticals, Inc. (0001130166) (Subject)
SC 13G/A - Cyclacel Pharmaceuticals, Inc. (0001130166) (Subject)